


## Miglustat hydrochloride

## Chemical Properties

|                   |   |
|-------------------|---|
| CAS No. :         | 210110-90-0   |
| Formula:          | C <sub>10</sub> H <sub>22</sub> ClNO <sub>4</sub>   |
| Molecular Weight: | 255.74  |
| Storage:          | Powder: -20°C for 3 years   In solvent: -80°C for 1 year<br>Actual storage temperature shall be subject to the COA. |



## Biological Description

|               |   |
|---------------|---|
| Description   | Miglustat hydrochloride (N-Butyldeoxynojirimycin hydrochloride) is an inhibitor of glucosylceramide synthase and can be used for studies about Type I Gaucher disease.  |
| Targets(IC50) | Transferase   |
| In vivo       | Consumption of a standard high-fat breakfast within 30 minutes before administration of Miglustat hydrochloride significantly reduced peak exposure but did not significantly affect the extent of systemic exposure to Miglustat hydrochloride. The C <sub>max</sub> decreased by 36% on average following administration with food. AUC showed a modest (14%) decrease with food, but the 90% confidence interval was within the acceptance limit of 80% to 125%. T <sub>max</sub> was prolonged from 2.5 (1.0-4.0) hours in the fasted state to 4.5 (1.5-8.0) hours in the fed state, whereas the apparent terminal half-life was approximately 8 hours and not affected by food[1]. |

## Solubility Information

|                     |  |
|---------------------|--|
| Solubility          | H <sub>2</sub> O: 34 mg/mL (132.95 mM),Sonication is recommended.<br>DMSO: 60 mg/mL (234.61 mM),Sonication is recommended.<br>(< 1 mg/ml refers to the product slightly soluble or insoluble)  |
| In vivo Formulation | 10% DMSO+40% PEG300+5% Tween 80+45% Saline: 2.5 mg/mL (9.78 mM),Sonication is recommended.<br><i>Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions.</i> |

### Preparing Stock Solutions

---

|       | 1mg       | 5mg        | 10mg       |
|-------|-----------|------------|------------|
| 1 mM  | 3.9102 mL | 19.5511 mL | 39.1022 mL |
| 5 mM  | 0.782 mL  | 3.9102 mL  | 7.8204 mL  |
| 10 mM | 0.391 mL  | 1.9551 mL  | 3.9102 mL  |
| 50 mM | 0.0782 mL | 0.391 mL   | 0.782 mL   |

---

Please select the appropriate solvent to prepare the stock solution, according to the solubility of the product in different solvents. Please use it as soon as possible.

Note: The dilution table applies only to solid products. For liquid products, please calculate the stock solution based on the stated concentration and/or density.

### Reference

van Giersbergen, P.L. and J. Dingemans, Influence of food intake on the pharmacokinetics of miglustat, an inhibitor of glucosylceramide synthase. *J Clin Pharmacol*, 2007. 47(10): p. 1277-82.

Abian, O., et al., Therapeutic strategies for Gaucher disease: miglustat (NB-DNJ) as a pharmacological chaperone for glucocerebrosidase and the different thermostability of velaglucerase alfa and imiglucerase. *Mol Pharm*, 2011. 8(6): p. 2390-7.

**Inhibitor · Natural Compounds · Compound Libraries · Recombinant Proteins**

This product is for Research Use Only · Not for Human or Veterinary or Therapeutic Use

Tel:781-999-4286 E\_mail:info@targetmol.com Address:34 Washington Street,Wellesley Hills,MA 02481